Mary Reilly

Has grant

Professor of Clinical Neurology and Consultant Neurologist

Country flagUnited Kingdom

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Mary Reilly is a Professor of Clinical Neurology and Consultant Neurologist at The National Hospital for Neurology and Neurosurgery in the UK. Her research primarily focuses on peripheral neuropathies, including hereditary transthyretin-mediated amyloidosis and Charcot-Marie-Tooth disease. Recent publications highlight her work on the clinical characteristics and genetic factors associated with these conditions, as well as the importance of early diagnosis in treating TTR amyloidosis.

Recent Grants

Grant: Close

• CMTA Hereditary Sensory Neuropathy Serine trial (SENSE trial)

Open Date: 2022-03-01

Close Date: 2025-02-01

Grant: Close

Preventable axon degeneration in human disease G

Open Date: 2021-10-01

Close Date: 2026-09-01

Grant: Close

NIH CMT1X Biomarkers and Outcome Measures

Open Date: 2021-06-01

Close Date: 2023-05-01

Grant: Close

NIH CMT2A Biomarkers and Outcome Measures

Open Date: 2021-06-01

Close Date: 2023-05-01

Grant: Close

• NIH CMT1B Biomarkers and Outcome Measures

Open Date: 2020-06-01

Close Date: 2022-05-01

Articles (15)

Year:

2025

Background and purpose Charcot−Marie−Tooth disease type 1A (CMT1A) is the most prevalent hereditary neuropathy worldwide and classically has slow nerve conduction velocity (NCV), in most cases below 38 m/s. Two unrelated patients with motor NCVs in the upper limbs above 38 m/s are reported. Method Case report. Results Two genetically confirmed CMT1A patients are presented, from two unrelated families (one of British origin and the other of Brazilian origin). Both individuals had upper limb motor NCVs above 38 m/s, with values ranging from 41.9 to 45 m/s in the median nerve and from 42 to 42.3 m/s in the ulnar nerve. They presented with a very mild phenotype, with CMT Neuropathy Score version 2 (CMTNSv2) of 6 and 5, respectively. In contrast, affected family members within both kinships exhibited a classical phenotype with more severe disease manifestation (CMTNSv2 ranging from 12 to 20) and motor NCVs below 30 m/s. Conclusion These cases, although very rare, highlight the importance of testing PMP22 duplication in patients with intermediate conduction velocities.

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

Michael P Lunn

University College London

UNITED KINGDOM
View details

Matteo Ferla

University of Oxford

UNITED KINGDOM
View details

Julian D Gillmore

University College London

UNITED KINGDOM
View details

Diego Kaski

Consultant Neurologist and Senior Lecturer

-

UNITED KINGDOM
View details

Huw Morris

University College London

UNITED KINGDOM
View details

Vincent Picher-Martel

Professeur Médecin Adjoint sous octroi

Laval University

CANADA
View details

Gita Ramdharry

Honorary Associate Professor

UCL Institute of Neurology, University College London

UNITED KINGDOM
View details

Matilde Laurá

-

UNITED KINGDOM
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.